Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Karie Beasley

Nurse Practitioner, Gerontology Evansville, IN Nurse Practitioner

NPI 1134601214 CMS profile 10979482

4962 Lincoln Ave Ste 101, Evansville, IN 47715

Open in the dashboard

General payments

$13,472

893 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Karie Beasley of Evansville, IN is reported in the CMS Open Payments database as having received $13,472 across 893 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,655 107
2024 General $700 28
2023 General $3,344 238
2022 General $3,997 260
2021 General $3,776 260

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Karie Beasley
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Karie Beasley were reported at $1,655. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Karie Beasley Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $3,776 $133 $44–$396 $132
2022 $3,997 $142 $48–$452 $149
2023 $3,344 $158 $53–$482 $160
2024 $700 $171 $55–$533 $164
2025 $1,655 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,648 139 payments
  2. Gilead Sciences, Inc. $1,120 21 payments
  3. Otsuka America Pharmaceutical, Inc. $1,015 62 payments
  4. ViiV Healthcare Company $954 65 payments
  5. Amgen Inc. $770 63 payments
  6. ITI, Inc. $728 40 payments
  7. Novo Nordisk Inc $686 56 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $526 50 payments
  9. Lundbeck LLC $495 40 payments
  10. Pfizer Inc. $454 29 payments
  11. Other $5,074 328 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,057 885 payments
  2. Education $415 8 payments
Products named General payments · program years 2021–2025
  1. REXULTI $921 56 payments
  2. VRAYLAR $846 66 payments
  3. Ozempic $605 50 payments
  4. RYBELSUS $567 47 payments
  5. SYMTUZA $478 13 payments
  6. Repatha $467 39 payments
  7. DOVATO $465 36 payments
  8. CAPLYTA $390 22 payments
  9. LYBALVI $376 26 payments
  10. NURTEC ODT $369 24 payments
  11. Other $11,369 841 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

1,884

Median for Nurse Practitioner: 389

Drug cost

$836,753

Median for Nurse Practitioner: $21,885

Branded share of claims

28.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Symtuza Darunavir/Cob/Emtri/Tenof Alaf Brand 68 $324,768
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 51 $207,787
Jardiance Empagliflozin Brand 68 $59,779
Dovato Dolutegravir Sodium/Lamivudine Brand 12 $35,117
Ozempic Semaglutide Brand 26 $33,981
Vraylar Cariprazine Hcl Brand 15 $23,827
Linzess Linaclotide Brand 28 $21,872
Rexulti Brexpiprazole Brand 14 $21,709
Vascepa Icosapent Ethyl Brand 39 $20,828
Trulicity Dulaglutide Brand 16 $19,752

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$495,800

Of which drugs: $490,881

Medicare patients

80

Average age 68

Services billed

16,270

44 women, 36 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 55%
Depression 40%
Diabetes 31%
Osteoporosis 28%
Ischemic heart disease 26%
Chronic kidney disease 26%
COPD 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Infusion, normal saline solution, 250 cc J7050 Office 18 51 $27

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $43
  • Lundbeck LLC $19
$61 14 —
CABENUVA
  • ViiV Healthcare Company $41
$41 — —
LINZESS
  • AbbVie, Inc. $30
$30 28 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $21
$21 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

893 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record